Allogene Therapeutics Announces Q2 Investor Conference Participation
09 4월 2024 - 9:30PM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) products for cancer and autoimmune disease, today
announced that it will participate in four investor conferences in
the second quarter of 2024.
Canaccord Genuity Horizons in Oncology Virtual
ConferenceMonday, April 15, 202412:00pm PT/3:00pm ET
JPM Securities Life Sciences Conference
Tuesday, May 14, 20246:00am PT/9:00am ET
2024 RBC Capital Markets Global Healthcare
Conference Wednesday, May 15, 20248:00am PT/11:00am ET
Goldman Sachs 45th
Annual Healthcare Conference Tuesday, June 11,
20245:40am PT/8:40am ET
Any available webcasts will be posted to the Company's website
at www.allogene.com under the Investors tab in the News and Events
section. Following a live webcast, a replay will be available on
the Company's website for approximately 30 days.
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the
development of allogeneic chimeric antigen receptor T cell
(AlloCAR T™) products for cancer and autoimmune disease. Led by a
management team with significant experience in cell therapy,
Allogene is developing a pipeline of “off-the-shelf” CAR T cell
product candidates with the goal of delivering readily
available cell therapy on-demand, more reliably, and
at greater scale to more patients. For more information,
please visit www.allogene.com, and follow @AllogeneTx on X
(formerly Twitter) and LinkedIn.
Cautionary Note on Forward-Looking Statements for
AllogeneThis press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements regarding intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things Allogene’s ability to develop and deliver
readily available allogeneic CAR T products for the treatment of
cancer and autoimmune disease on-demand, more reliably, and at
greater scale to more patients. Various factors may cause material
differences between Allogene’s expectations and actual results,
including risks and uncertainties related to our product candidates
are based on novel technologies, which makes it difficult to
predict the time and cost of product candidate development, the
safety or efficacy of a product candidate, and whether a product
candidate will receive regulatory approval, which could prevent or
delay commercialization. These and other risks are discussed in
greater detail in Allogene’s filings with the SEC, including
without limitation under the “Risk Factor” heading in its Annual
Report on Form 10-K filed for the year ended December 31,
2023. Any forward-looking statements that are made in this press
release speak only as of the date of this press release. Allogene
assumes no obligation to update the forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics,
Inc.
Allogene Media/Investor Contact:Christine
CassianoEVP, Chief Corporate Affairs & Brand Strategy
OfficerChristine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Allogene Therapeutics (NASDAQ:ALLO)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024